Cambridge, MA - June 23, 2009

Cerulean Pharma Inc. Announces License Agreement with Calando Pharmaceuticals, Inc., a Subsidiary of Arrowhead Research Corporation.

Cerulean Pharma Inc., a biopharmaceutical company focused on developing intelligently designed, nanoparticle-based drugs, announced today that it has entered into an exclusive, worldwide license agreement with Calando Pharmaceuticals, Inc . More >>


Cerulean Pharma
Pioneering the Field of Nanobiology


Nanopharmaceuticals are a revolutionary new approach to designing drugs within ultra-small particles and enhancing their properties with the goal of creating improved therapies for fighting disease.

Within the field of nanopharmaceuticals, Cerulean Pharma is uniquely focused on a next-generation approach we call Nanobiology. Cerulean’s nanobiology-based drug development is based on a deep understanding of the complex biological microenvironment of human disease combined with engineering therapies on a nanoscale, enabling the creation of breakthrough drugs that optimally target the root causes of disease.


Conventional Chemotherapy
vs
Nanopharmaceutical Chemotherapy


View Movie

Company :: Technology :: Careers :: News :: Contact :: Home :: Privacy Policy :: Terms & Conditions of Use
Cerulean Pharma Inc. 161 First Street Cambridge, MA 02142     p 617 551 9600    f 617 494 1544
Copyright 2008 © Cerulean Pharma, Inc. All rights reserved.